Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... SAN RAMON, Calif., Aug. 20 HRI, a San Francisco ... leading the way in helping California healthcare employers comply with ... effect August 5th. , , California is ... from exposure to infectious airborne diseases, including the H1N1 flu. ...
... TITUSVILLE, N.J., Aug. 21 The U.S. Food and ... the New Drug Application (NDA) for carisbamate, an anti-epileptic ... , The NDA, filed in October 2008 ... (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. seeks approval ...
Cached Medicine Technology:San Ramon HR Firm Leads Response to New Cal/OSHA ATD Law 2FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
(Date:9/21/2014)... 2014 An experienced review website in ... hosting ranking list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ... suppliers. , There has been a boom in ... resulted in an increase in the number of web ... at very affordable prices. VPS (Virtual Private Server) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... by Dr. Kenneth Pullman that is helping thousands of ... their diabetes symptoms without shots, pills, or prescriptions has ... review. , “There are currently tens of millions ... both Type 1 and Type 2 diabetes, and unfortunately, ...
(Date:9/20/2014)... Islands of Loreto, Baja, Mexico (PRWEB) September 20, 2014 ... of Loreto today announced the resort did not experience ... fully operational, with all amenities and activities available. , ... September 14, 2014, bringing intense wind, rain and powerful ... Baja Peninsula, Villa del Palmar Islands of Loreto experienced ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... following Congress, failure,to override SCHIP veto, WASHINGTON, Oct. ... Fattah:, "It,s a sad day when America,s children ... for and look after their most basic needs. It,s,a ... defend its most,vulnerable citizens., "The failure of the ...
... Must Happen Before Congressional Thanksgiving Break on State,Children,s ... "Congress cannot go home,to its Thanksgiving break ... of mind for America,s laboring families by passing ... Delgado, President and CEO of the,National Alliance for ...
... the Northern California Cancer Center, the University of Southern ... found that increased exposure to sunlight which increases ... decrease the risk of advanced breast cancer. , In ... Journal of Epidemiology, the researchers found that women with ...
... 2007 Research will be reported at TCT 2007, ... (CRF), that demonstrates that early intervention saves lives in ... pain. , Responding to media reports of recent studies ... to men, Dr. Alexandra J. Lansky, MD, Director of ...
... half of sufferers are kept awake by a variety of ... Along with typical symptoms such as acid reflux, the less ... coughing, choking, wheezing, choking, snoring, sore throat, and chest pain ... new U.S. survey. , The poll of 701 GERD patients ...
... Oct. 18 Following is a statement from ... the House,s failure to,override President Bush,s veto of ... of the Congressional Democrats and,some courageous Republicans to ... health care to children whose parents cannot,afford it. ...
Cached Medicine News:Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 2Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 3Health News:Are women at greater risk from angioplasty? 2
Wire lid retractor, may be clamped to surgical drape with suture or elastic band. Small pair....
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medicine Products: